Artisan Partners (NYSE:APAM) Surprises With Q2 CY2026 Sales

Artisan Partners (NYSE:APAM) reported Q2 CY2026 sales of $307.9 million, up 8.9% year on year and 2.3% above analysts’ revenue estimates, according to the company. Non-GAAP EPS was $0.94, about 3% above consensus. AUM was $183.4 billion, 4.5% higher year on year and in line with expectations.

Original reporting
Published Jul 28, 2026, 10:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 10:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Artisan Partners (NYSE:APAM) Surprises With Q2 CY2026 Sales — source image
Decision brief

The 30-second read

$APAMBullishLow
01

Why it matters

The key tradable takeaway is the Q2 beat on revenue and EPS, plus the reported AUM level and YoY growth, but there is no new guidance or flow detail to materially change forward expectations.

02

Market read

Consensus-beating Q2 results can support near-term positioning, but the lack of forward-looking catalysts and the flat immediate stock reaction reduce urgency.

03

What to watch

AUM growth is described as meeting expectations, but the text says fundraising or short-term investment performance was a net detractor over the last two years, which could pressure future flows.

Relevance 5/10Novelty 5/10Timing: after-hours/late-day reaction to Q2 CY2026 results

Background

Artisan Partners is an active investment manager; the article frames results around revenue growth, AUM, and non-GAAP EPS versus consensus.

Company-level read

Ticker impact

$APAMBullishMedium confidence
Context

Artisan Partners reported Q2 CY2026 revenue of $307.9M, up 8.9% YoY, beating Wall Street estimates by 2.3%.

Expected impact

Likely modest positive bias for the stock, though the article notes shares were flat at $41.15 immediately after results.

Evidence & confidence

The piece provides concrete Q2 beats (revenue and non-GAAP EPS) and a same-day price reaction (flat), but it lacks forward guidance or new AUM/flow drivers beyond the reported AUM level.

Market effects

Signals resilience in active asset management demand and fee revenue, but without new industry-wide data.

No specific regional catalyst beyond US-listed results.

No global macro or cross-border transaction details provided.

Counterpoint

The article highlights long-term sluggish revenue growth (2.8% CAGR over five years), implying the beat may be partly cyclical rather than a durable re-acceleration.

Key entities

  • Artisan Partners

    Reported Q2 CY2026 revenue and non-GAAP EPS versus Wall Street estimates, and provided AUM and YoY growth figures.

Related articles

$APAMMed

Artisan Partners Asset Management Inc. (APAM): Results of Operations and Financial Condition

Artisan Partners Asset Management Inc. (APAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 artisan2q26earningsrelease.htm EARNINGS RELEASE OF ARTISAN PARTNERS ASSET MANAGEMENT INC. DATED JULY 28, 2026 Document Artisan Partners Asset Management Inc. Reports 2Q26 Results and Quarterly Dividend Milwaukee, WI - July 28, 2026 - Artisan Partners Asset Management In

$APAMMed

Why is Aperam stock sliding today? By Investing.com

Aperam shares fell 3.7% to €43.44 after BNP Paribas Exane downgraded the stock from neutral to underperform and set a €38.00 price target, below recent levels. The article cites InvestingPro fair value of €40.12 and notes the stainless steel sector faces cautious sentiment. Aperam’s next earnings are due July 30.

$PFEMedAI 8/10

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer (PFE) and BioNTech (BNTX) reported Q2 2026 results and updates after the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29. Pfizer posted Q2 revenue of $15.0B, Adjusted EPS $0.77, and raised full-year revenue guidance to $60.5–$62.5B. BioNTech’s Q2 revenue fell 59.5% to €105.6M and net loss widened to €820.8M, with guidance cut to €1.6–€1.9B.